wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 4% in a human being.

2. The dosage form of claim 1, comprising about 1 mg to about 600 mg of zoledronic acid.

3. The dosage form of claim 1, comprising about 10 mg to about 300 mg of zoledronic acid.

4. The dosage form of claim 1, comprising about 20 mg to about 50 mg of zoledronic acid.

5. The dosage form of claim 1, comprising about 50 mg to about 100 mg of zoledronic acid.

6. The dosage form of claim 1, comprising about 100 mg to about 200 mg of zoledronic acid.

7. The dosage form of claim 1, wherein the dosage form is solid.

8. The dosage form of claim 1, wherein the dosage form is to be orally administered.

9. The dosage form of claim 1, wherein at least 10% of the weight of the dosage form is zoledronic acid.

10. The dosage form of claim 1, wherein the dosage form is suitable for administration to a human being.

11. The dosage form of claim 1, wherein the bioavailability of zoledronic acid in the dosage form is from about 1.3% to about 4% in a human being.

12. The dosage form of claim 1, wherein the bioavailability of zoledronic acid in the dosage form is from about 1.5% to about 4% in a human being.

13. The dosage form of claim 1, wherein the dosage form is a tablet.

14. The dosage form of claim 1, wherein the dosage form is a capsule.

15. The dosage form of claim 1, for use in treating complex regional pain syndrome.

16. The dosage form of claim 1, for use in treating arthritis.

17. The dosage form of claim 1, for use in treating knee pain.

18. The dosage form of claim 10, for use in treating knee pain, wherein the human being has OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing.

19. The dosage form of claim 1, for use in treating low back pain.

20. The dosage form of claim 1, for use in treating a bone marrow lesion.

21. The dosage form of claim 1, wherein the zoledronic acid is in a disodium salt form or an acid form.

22. The dosage form of claim 3, comprising about 40 mg to about 60 mg of zoledronic acid.

23. The dosage form of claim 22, comprising an equivalent of about 50 mg of zoledronic acid in a disodium salt form.

24. The dosage form of claim 23, wherein the dosage form is to be orally administered to a human being weekly for 6 weeks, and the resulting area under the plasma concentration curve (AUC) of zoledronic acid is about 100 ng•h/mL to about 2000 ng•h/mL in the human being.

25. The dosage form of claim 23, wherein the zoledronic acid is in a hydrate form.